ROYALTY PHARMA OA DL-0001 Logo
GB00BMVP7Y09
A2P62D
RPRX

ROYALTY PHARMA OA DL-0001

Kurser indlæses...

Prognose

Analytikernes gennemsnitlige kursmål er 60,49 € (-2,42 %). Medianen er 60,49 € (-2,42 %).

Køb
  11
Behold
  0
Sælg
  0

Diskussioner i communityet

  • Cashflow Depot 500 Euro Netto bis 2030

    Stefan Weiprecht Stefan Weiprecht II i Portfolio Roasts

    13 23

  • Royalty Pharma expands business model: R&D co‑funding, China expansion and AI in focus

    At the Morgan Stanley Healthcare Conference, Royalty Pharma said its business has evolved well beyond pure royalties. The company reached its five‑year capital deployment target of $10–12bn earlier than planned, is expanding an R&D co‑funding business with partners such as Biogen, Teva Pharm and Johnson & Johnson, and is expanding into China. Royalty Pharma is also investing heavily in data science and AI for due diligence; portfolio returns remain attractive while management factors in development failures. » Mere på de.investing.com


  • Pelacarsen study fails, Royalty Pharma still expects moderate return

    Novartis’s Phase 3 HORIZON study of pelacarsen missed its primary endpoint for reducing cardiovascular events versus placebo. Royalty Pharma expects, based on its $500 million financing agreement with Ionis, to recover its invested capital and achieve a moderate positive return without making milestone payments to Ionis. The agreement covers investments in pelacarsen and Spinraza royalties; the claim on Spinraza revenues yields roughly a 1.1× return under current terms. The company reaffirmed its goal of generating at least $4.7 billion in portfolio revenue by 2030. » Mere på de.investing.com


  • Royalty Pharma reaches record high at $62.48

    Royalty Pharma’s stock rose to a new record high of $62.48 and is currently trading at $62.58, implying a market capitalization of $35.87 billion. Year to date the shares are up 69.78%. For Q2 2026 the company reported licensing revenue of $768 million (+14% year over year) and portfolio revenue of $773 million (+6%), after which BofA raised its price target from $62.00 to $63.00 and kept its rating at "Buy." However, an analysis by InvestingPro classifies the stock as overvalued relative to its fair value. » Mere på de.investing.com


  • Royalty Pharma reaches record high of $60.44

    Royalty Pharma’s stock rose to a record high of $60.44 and is trading near its 52-week high after gaining 69% last year. For Q2 2026 the company reported royalties of $768 million (+14%) and portfolio revenues of $773 million (+6%), after which the full-year guidance was raised for the second time. BofA raised its price target to $63.00 and reiterated a “buy” rating, citing strong sales of products such as Tremfya, Voranigo, Imdelltra and Evrysdi. » Mere på de.investing.com


  • Royalty Pharma announces quarterly dividend of US$0.235

    Royalty Pharma has declared a dividend of US$0.235 per Class A common share for the third quarter of 2026. The payment will be made on 10 September 2026 to shareholders of record at the close of trading on 14 August 2026. The current dividend yield is 1.61%; the company has raised the dividend for six consecutive years. Royalty Pharma invests in biopharmaceutical royalties and recorded a 69% share price increase last year, trading near its 52‑week high of US$58.84. » Mere på de.investing.com

I 2026 har ROYALTY PHARMA OA DL-0001 allerede udloddet 0,72 € i udbytte. Den seneste udlodning fandt sted i september.

Virksomhedstal

I det seneste kvartal havde ROYALTY PHARMA OA DL-0001 en omsætning på 609,26 mio. € og et nettoresultat på 127,73 mio. €
(EUR) september 2026
YoY
Omsætning 609,26 mio. 17,35 %
Bruttofortjeneste 609,26 mio. 17,35 %
Nettoresultat 127,73 mio. 47,99 %
EBITDA 310,58 mio. 30,58 %

Fundamentale data

Nøgletal Værdi
Markedsværdi
27,64 mia. €
Antal aktier
445,27 mio.
Højeste/laveste i 52 uger
64,01 € - 33,94 €
Udbytteafkast
1,48 %
Udbytte TTM
0,93 €
Næste udbytte
0,24 €
Beta
0,41
P/E (PE Ratio)
40,85
PEG (PEG Ratio)
-1,80
K/I (PB Ratio)
4,45
P/S (PS Ratio)
11,61

Virksomhedsprofil

Royalty Pharma plc opererer som køber af royalties inden for biofarmaceutiske produkter og som finansiel støttegiver af innovationer i den biofarmaceutiske industri i USA. Virksomheden er også involveret i identifikation, evaluering og erhvervelse af royalties på forskellige biofarmaceutiske behandlinger. Derudover samarbejder virksomheden med innovatører fra akademiske institutioner, forskningshospitaler og non-profit-organisationer, små og mellemstore biotekvirksomheder samt farmaceutiske virksomheder. Porteføljen består af royalties på ca. 35 markedsførte behandlinger og 10 produktkandidater under udvikling, som dækker forskellige terapiområder, såsom sjældne sygdomme, kræft, neurologi, infektionssygdomme, hæmatologi og diabetes. Virksomheden blev grundlagt i 1996 og har hovedkontor i New York, New York.

Navn
ROYALTY PHARMA OA DL-0001
CEO
Pablo Legorreta
Hjemsted New York, ny
USA
Websted
Sektor
Sundhed
Branche
Sundhedsudbydere og -tjenester
Børsnotering
16.06.2020
Medarbejdere 100

Tickersymboler

Børs Symbol
NASDAQ
RPRX
Frankfurt
RPD.F
Düsseldorf
RPD.DU
München
RPD.MU
SIX
RPRX.SW
XETRA
RPD.DE
Hamburg
RPD.HM
🍪

Parqet  bruger cookies. Læs mere